SC
IKT icon

SummitTX Capital’s Inhibikase Therapeutics IKT Stock Holding History

SummitTX Capital’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.61M Buy
1,780,262
+255,726
+17% +$458K 0.09% 239
2026
Q1 		$2.56M Buy
+1,524,536
New +$2.71M 0.08% 262

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SummitTX Capital's IKT Position: Q2 2026 in Review

SummitTX Capital increased its Inhibikase Therapeutics (IKT) stake by 17% in Q2 2026, buying an estimated $458K and bringing the position to 1,780,262 shares worth $3.61M. The position accounts for 0.09% of the portfolio, ranked #239.

SummitTX Capital first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • SummitTX Capital held 1,780,262 shares of Inhibikase Therapeutics worth $3.61M as of Q2 2026.
  • SummitTX Capital bought 255,726 Inhibikase Therapeutics shares in Q2 2026, an estimated $458K.
  • Inhibikase Therapeutics made up 0.09% of SummitTX Capital's portfolio in Q2 2026, its #239 holding.
  • SummitTX Capital first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.